The report evaluated 15 of the largest commercial formularies for prescription drugs in the U.S. to determine how they matched fair access criteria developed by ICER.
A new report attempts to pierce the veil of drug pricing and insurance coverage, an area that is marked by a lack of industry data and a surfeit of horror stories from consumers. Overall, the report noted the limitations of its conclusions but found that most payers seemed to be providing fair access for the drugs in the analysis, based on the available data.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
